These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of anakinra in patients with ST-elevation myocardial infarction. Liu XH; Zhang L Int J Cardiol; 2024 Sep; 411():132297. PubMed ID: 38936429 [No Abstract] [Full Text] [Related]
6. Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade. Chu CQ J Rheumatol; 2010 Apr; 37(4):881-2. PubMed ID: 20360207 [No Abstract] [Full Text] [Related]
7. Interleukin-1 blockade for recurrent pericarditis: insights from the real-world experience. Lazaros G; Tsioufis K; Vassilopoulos D J Pediatr; 2023 Jul; 258():113354. PubMed ID: 36963480 [No Abstract] [Full Text] [Related]
8. In-perspective: the ARAMIS double-blind randomized placebo-controlled trial of anakinra for the treatment of acute myocarditis. Morrow DA; Verbrugge FH Eur Heart J Acute Cardiovasc Care; 2023 Sep; 12(9):627-628. PubMed ID: 37648656 [No Abstract] [Full Text] [Related]
9. Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system. Mahmoudi Azar L; Karaman E; Beyaz B; Göktan I; Eyüpoğlu AE; Kizilel S; Erman B; Gül A; Uysal S BMC Biotechnol; 2023 Jun; 23(1):15. PubMed ID: 37340430 [TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-1 in perinatal inflammation and its impact on transitional circulation. Owen JC; Garrick SP; Peterson BM; Berger PJ; Nold MF; Sehgal A; Nold-Petry CA Front Pediatr; 2023; 11():1130013. PubMed ID: 36994431 [TBL] [Abstract][Full Text] [Related]
11. The Role of the Interleukin-1 Family in Complications of Prematurity. Green EA; Garrick SP; Peterson B; Berger PJ; Galinsky R; Hunt RW; Cho SX; Bourke JE; Nold MF; Nold-Petry CA Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769133 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature. Jeria-Navarro S; Gomez-Gomez A; Park HS; Calvo-Aranda E; Corominas H; Pou MA; Diaz-Torne C Front Med (Lausanne); 2022; 9():1089993. PubMed ID: 36714095 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Pisaniello HL; Fisher MC; Farquhar H; Vargas-Santos AB; Hill CL; Stamp LK; Gaffo AL Arthritis Res Ther; 2021 Apr; 23(1):130. PubMed ID: 33910619 [TBL] [Abstract][Full Text] [Related]
14. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. Köhler BM; Günther J; Kaudewitz D; Lorenz HM J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31261785 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Lopalco G; Cantarini L; Vitale A; Iannone F; Anelli MG; Andreozzi L; Lapadula G; Galeazzi M; Rigante D Mediators Inflamm; 2015; 2015():194864. PubMed ID: 25784780 [TBL] [Abstract][Full Text] [Related]
16. An expanding role for interleukin-1 blockade from gout to cancer. Dinarello CA Mol Med; 2014 Dec; 20 Suppl 1(Suppl 1):S43-58. PubMed ID: 25549233 [TBL] [Abstract][Full Text] [Related]
17. The emerging role of biotechnological drugs in the treatment of gout. Cavagna L; Taylor WJ Biomed Res Int; 2014; 2014():264859. PubMed ID: 24839602 [TBL] [Abstract][Full Text] [Related]
19. Treating inflammation by blocking interleukin-1 in humans. Dinarello CA; van der Meer JW Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598 [TBL] [Abstract][Full Text] [Related]
20. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Ramasamy SN; Korb-Wells CS; Kannangara DR; Smith MW; Wang N; Roberts DM; Graham GG; Williams KM; Day RO Drug Saf; 2013 Oct; 36(10):953-80. PubMed ID: 23873481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]